Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has The Cervical Cancer Diagnostics Market Size Shifted, And What Is the Outlook Through 2034?

The market size for cervical cancer diagnostics has seen robust growth in the past few years. The market valuation is expected to increase from $9.27 billion in 2024 to $9.85 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.2%. The historic growth is linked to factors such as enhanced awareness and screening initiatives, HPV vaccinations, technological advances, and an aging population.

How Much Will the Cervical Cancer Diagnostics Market Be Worth in 2029?

In the forthcoming years, the cervical cancer diagnostics market is anticipated to witness robust growth. It is predicted to escalate to $12.5 billion in 2029, growing at a compound annual growth rate (CAGR) of 6.1%. The rise during the forecast period can be linked to an increase in hpv-related cancers, evolving markets, advancements in molecular testing, telemedicine and remote screenings. Key trends predicted during this forecast period encompass hpv testing, liquid-based cytology, automation and digital pathology, and screen-and-treat programs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3285&type=smp

Which is the Largest Company in the Cervical Cancer Diagnostics Market?

Major companies operating in the cervical cancer diagnostics market include Abbott Laboratories, Becton Dickinson and Company (BD), Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Hologic Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Siemens Healthineers AG, Zilico Ltd., Guided Therapeutics Inc., Thermo Fisher Scientific Inc., Carl Zeiss AG, OncoHealth Corporation, Arbor Vita Corporation, Micromedic Technologies Ltd., Trovagene Inc., Roche Diagnostics, Nucleix Ltd., BGI Genomics Co. Ltd., Cepheid, Exact Sciences Corporation, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., PerkinElmer Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation

What Are the Main Market Drivers in the Cervical Cancer Diagnostics Industry?

The expanding utilization of cervical cancer diagnostic tests for early identification of cervical cancer is predicted to stimulate the cervical cancer diagnostics market. Enhanced awareness of cervical cancer among women, coupled with global cancer organizations and governments’ focus on early screening for cervical cancer detection and prevention, bolsters the market’s expansion. For instance, as per the Centers for Disease Control and Prevention, an American government agency, the U.S. recorded 12,536 new cervical cancer cases in July 2024 and 4,051 women lost their lives to the disease in 2022. The increasing usage of cervical cancer diagnostic tests and concentration on early detection spur the cervical cancer diagnostics market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3285&type=smp

How Is the Cervical Cancer Diagnostics Market Segments Structured?

The cervical cancer diagnostics market covered in this report is segmented –

1) By Diagnostic Test: Pap Smear Test, HPV Test, Colposcopy, Biopsy and Endocervical Curettage, Other Diagnostic Tests

2) By Age Group: Below 21, Age between 21 to 29, Age between 30 to 65, Above 65

3) By End User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers, Diagnostic Centers

Subsegments:

1) By Pap Smear Test: Conventional Pap Smear, Liquid-Based Pap Smear

2) By HPV Test: DNA-Based HPV Test, RNA-Based HPV Test, Hybrid Capture HPV Test, Other HPV Tests

3) By Colposcopy: Standard Colposcopy, Digital Colposcopy, Optical Colposcopy

4) By Biopsy And Endocervical Curettage: Punch Biopsy, Endocervical Curettage (ECC), Cone Biopsy, Colposcopic Biopsy

5) By Other Diagnostic Tests: Visual Inspection With Acetic Acid (VIA), Cervical Cytology Testing, Blood Tests, Other Specialty Tests

What Strategic Trends Are Transforming the Cervical Cancer Diagnostics Market?

Leading corporations in the cervical cancer diagnostics market are concentrating their efforts on creating innovative technological solutions, such as HPV self-collection methods for cervical cancer, to improve screening accessibility and boost early detection rates. The HPV self-collection method for cervical cancer is a procedure that enables individuals to gather their own samples for testing the human papillomavirus (HPV) which is a primary contributor to cervical cancer. For example, in May 2024, pharmaceutical company F. Hoffmann-La Roche AG, based in Switzerland, achieved FDA approval for their self-collection HPV solution, a notable progression in cervical cancer screening that enhances accessibility for individuals, especially those from underserved communities. This groundbreaking method permits women to discreetly obtain vaginal samples for examination using Roche’s Cobas molecular HPV test, reinforcing the World Health Organization’s 2030 objective to eradicate cervical cancer. This approval comes in the wake of the successful IMPACT trial, which confirmed the solution’s effectiveness in a range of demographics.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cervical-cancer-diagnostics-global-market-report

Which Global Regions Offer the Highest Growth in the Cervical Cancer Diagnostics Market?

North America was the largest region in the cervical cancer diagnostics market in 2023 Asia-Pacific was the second largest region in the cervical cancer diagnostics market. The regions covered in the cervical cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3285

This Report Delivers Insight On:

1. How big is the cervical cancer diagnostics market, and how is it changing globally?

2. Who are the major companies in the cervical cancer diagnostics market, and how are they performing?

3. What are the key opportunities and risks in the cervical cancer diagnostics market right now?

4. Which products or customer segments are growing the most in the cervical cancer diagnostics market?

5. What factors are helping or slowing down the growth of the cervical cancer diagnostics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model